2. Inhibitory Antibodies
  3. Tilogotamab

Tilogotamab  (Synonyms: GEN-1029; HexaBody-DR5/DR5; Hx-DR5-01/05)

Cat. No.: HY-P99559

Molarity Calculator

Tilogotamab (GEN-1029) is an agonistic hexamer formation-enhanced mixture of two antibodies that target two separate epitopes on death receptor type 5 (DR5). Tilogotamab specifically binds to and activates DR5. Tilogotamab can be used for the research of multiple myeloma (MM).

For research use only. We do not sell to patients.

CAS No. : 2109731-10-2

Size Stock
1 mg Get quote
5 mg Get quote

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Tilogotamab Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Tilogotamab (GEN-1029) is an agonistic hexamer formation-enhanced mixture of two antibodies that target two separate epitopes on death receptor type 5 (DR5). Tilogotamab specifically binds to and activates DR5. Tilogotamab can be used for the research of multiple myeloma (MM)[1].

Isotype

Human IgG1 kappa
Recommend Isotype Controls
Species

Humanized
In Vivo

Tilogotamab (20 μg/mL; 24 h) induces potent cytotoxicity of primary MM cells[1].
Tilogotamab is a mixture of 2 noncompeting DR5-specific immunoglobulin G1 (IgG1) antibodies, each with an E430G mutation in the Fc domain. This mutation enhances Fc-Fc interactions, resulting in antibody hexamerization, followed by FcγR-independent clustering of DR5 molecules[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
CAS No.
SMILES

[Tilogotamab]
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • Human IgG1 kappa
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Tilogotamab Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Tilogotamab2109731-10-2GEN-1029 HexaBody-DR5/DR5 Hx-DR5-01/05GEN1029GEN 1029OthersDR5death receptor type 5multiple myelomaInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Tilogotamab
Cat. No.:
HY-P99559
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (0 KB) Français - FR (0 KB) Deutsch - DE (0 KB) Norwegian - NO (0 KB) Español - ES (0 KB) Swedish - SV (0 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.